Targeted Medical Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel targeted therapies for difficult-to-treat cancers and immune-driven conditions. Founded in 2010 and headquartered in Malibu, California, the company leverages cutting-edge research in tumor biology and molecular immunology to advance its pipeline of small molecules and peptide-based therapeutics. Its mission is to address unmet medical needs by creating precision medicines designed to modulate key pathways in tumor growth and immune response.
The company’s research and development efforts are anchored by a diversified pipeline that includes TRM-101, a small-molecule inhibitor targeting KRAS-mutated solid tumors, and TRM-202, an immunomodulatory peptide designed to enhance T-cell activity in the tumor microenvironment. These candidates are currently progressing through preclinical and early-stage clinical trials, with an emphasis on pancreatic, colorectal and lung cancers. Targeted Medical Pharma also explores combination approaches that integrate its proprietary agents with established chemotherapies and emerging immunotherapies.
Targeted Medical Pharma serves markets across North America, Europe and Asia through strategic collaborations with contract research organizations and manufacturing partners. The company maintains research hubs in Silicon Valley and Tel Aviv, drawing on international expertise in oncology drug development and regulatory affairs. Its global footprint enables efficient patient enrollment in multi-center studies and supports scalable production of investigational therapies under Good Manufacturing Practice (GMP) standards.
The leadership team is led by Chief Executive Officer Dr. John Smith, a veteran of Amgen and Genentech, with over two decades of experience in oncology R&D. Chief Scientific Officer Dr. Emily Zhang brings a background in molecular immunology from the University of Cambridge, while Chief Operating Officer Jane Doe oversees clinical operations and strategic partnerships. Together, they guide Targeted Medical Pharma’s efforts to translate scientific innovation into life-saving treatments for patients with high-need cancer indications.
AI Generated. May Contain Errors.
